UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway
Drug Design, Development and Therapy · 2023
DOI: 10.2147/dddt.s405450 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2023. Verfasst von Yang Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of Ch…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.
Zitieren
APA
Wang, Y., Gao, G., Wei, X., Zhang, Y., & Yu, J. (2023). UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s405450
Vancouver
Wang Y, Gao G, Wei X, Zhang Y, Yu J. UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway. Drug Design, Development and Therapy. 2023. doi:10.2147/dddt.s405450
BibTeX
@article{Wang2023,
author = {Wang, Yang and Gao, Ge and Wei, Xiangpin and Zhang, Yang and Yu, Jian},
title = {UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway},
journal = {Drug Design, Development and Therapy},
year = {2023},
doi = {10.2147/dddt.s405450}
}
EUVIMED